N⁶-hydroxy-6-aminocaproic acid | 250215-06-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N⁶-hydroxy-6-aminocaproic acid
• 英文别名: 6-(Hydroxyamino)hexanoic acid
• CAS: 250215-06-6
• 化学式: C₆H₁₃NO₃
• 分子量: 147.174
• InChiKey: VIWLVGCOYOWRKS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.9
• 重原子数：
  10
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  69.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  乙酰氯 、 N⁶-hydroxy-6-aminocaproic acid 在 碳酸氢钠 作用下， 以 乙腈 为溶剂， 反应 12.0h， 生成 N⁶-acetyl-N⁶-hydroxy-6-aminocaproic acid
  参考文献：
  名称：

  Practical Synthesis of Hydroxamate-Derived Siderophore Components by an Indirect Oxidation Method and Syntheses of a DIG−Siderophore Conjugate and a Biotin−Siderophore Conjugate

  摘要：

  A practical large-scale synthesis of hydroxamate-derived siderophore components (30 and 40) that utilizes an efficient indirect oxidation method is described and applied to the syntheses of nonradioactive labeled siderophores. Oxidation of imines derived from L-ornithine (17) and its tripeptide (19) afforded oxaziridines that were isomerized to stable-nitrones (16 and 18). Acid-catalyzed hydrolysis of nitrones provided hydroxylamines that were converted to the desired hydroxamic acids (30 and 40) suitable for constructing siderophore-drug conjugates (2). The entire synthetic sequence required no chromatographic separation. DIG- and biotin-labeled ferrichrome analogues designed to detect and isolate ferrichrome receptors in various microbes were also synthesized.

  DOI：

  10.1021/jo990769y
• 作为产物：
  描述：

  2-(5'-carboxyl)-3-phenyloxaziridine 在 水 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 以300 mg的产率得到N⁶-hydroxy-6-aminocaproic acid
  参考文献：
  名称：

  Practical Synthesis of Hydroxamate-Derived Siderophore Components by an Indirect Oxidation Method and Syntheses of a DIG−Siderophore Conjugate and a Biotin−Siderophore Conjugate

  摘要：

  A practical large-scale synthesis of hydroxamate-derived siderophore components (30 and 40) that utilizes an efficient indirect oxidation method is described and applied to the syntheses of nonradioactive labeled siderophores. Oxidation of imines derived from L-ornithine (17) and its tripeptide (19) afforded oxaziridines that were isomerized to stable-nitrones (16 and 18). Acid-catalyzed hydrolysis of nitrones provided hydroxylamines that were converted to the desired hydroxamic acids (30 and 40) suitable for constructing siderophore-drug conjugates (2). The entire synthetic sequence required no chromatographic separation. DIG- and biotin-labeled ferrichrome analogues designed to detect and isolate ferrichrome receptors in various microbes were also synthesized.

  DOI：

  10.1021/jo990769y

文献信息

• Mesogen containing compounds
  申请人：TRANSITIONS OPTICAL, INC.

  公开号：EP2698412A2

  公开（公告）日：2014-02-19

  Compounds including at least one mesogenic substructure and at least one long flexible segment and methods of synthesizing the same,are disclosed. Formulations which include various embodiments of the mesogen containing compounds and their use in articles of manufacture and ophthalmic devices are also disclosed.

  本发明公开了包含至少一种介源亚基结构和至少一种长柔性段的化合物以及合成方法。此外，还公开了包括含介原化合物的各种实施方案的制剂及其在制造品和眼科设备中的用途。
• Primary N-hydroxylamines
  申请人：——

  公开号：US20040110729A1

  公开（公告）日：2004-06-10

  The invention provides pharmaceutical compositions comprising primary N-hydroxylamines and related therapeutic, prophylactic, diagnostic and screening methods. The pharmaceutical compositions generally comprise a pharmaceutical composition comprising an orally administrable effective unit solid dosage of a primary N-hydroxylamine or a pharmaceutically acceptable salt thereof and substantially free of a nitrone corresponding to the hydroxylamine.

  本发明提供了由伯胺基 N-羟胺组成的药物组合物以及相关的治疗、预防、诊断和筛查方法。这些药物组合物一般包括一种药物组合物，其中含有可口服的有效单位固体剂量的伯羟胺或其药学上可接受的盐，并且基本上不含与羟胺相对应的腈酮。
• [EN] BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF<br/>[FR] CONJUGUÉ À SUBSTANCE BIOACTIVE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION<br/>[ZH] 生物活性物偶联物及其制备方法和用途
  申请人：[en]MEDILINK THERAPEUTICS (SUZHOU) CO., LTD.;[zh]苏州宜联生物医药有限公司

  公开号：WO2022170971A1

  公开（公告）日：2022-08-18

  一种生物活性物偶联物及其制备方法和用途，涉及式XV所示的配体药物偶联物、其制备方法，以及其在预防和/或治疗与细胞活动异常相关的疾病，包括但不限于在预防和/或治疗肿瘤疾病中的用途。
• MESOGEN CONTAINING COMPOUNDS
  申请人：TRANSITIONS OPTICAL, INC.

  公开号：EP2698412B1

  公开（公告）日：2016-10-12
• US6455589B1
  申请人：——

  公开号：US6455589B1

  公开（公告）日：2002-09-24